Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses

被引：0

作者：

Harrison, Simon ^{[1
,2
]}

Riley, Caroline Hasselbalch ^{[3
]}

Manier, Salomon ^{[4
]}

Yoon, Sung-Soo ^{[5
]}

Pinto, Antonio ^{[6
]}

Cazaubiel, Titouan ^{[7
]}

Guidetti, Anna ^{[8
]}

Popat, Rakesh ^{[9
]}

Touzeau, Cyrille ^{[10
]}

Ocio, Enrique ^{[11
]}

Offner, Fritz ^{[12
]}

Rodriguez-Otero, Paula ^{[13
]}

Rizzello, Ilaria ^{[14
,15
]}

Mateos, Maria-Victoria ^{[16
]}

Broeske, Ann-Marie ^{[17
]}

Dekhtiarenko, Iryna ^{[18
]}

Dimier, Natalie ^{[19
]}

Eckmann, Jan ^{[17
,18
]}

Helms, Hans-Joachin ^{[20
]}

Jacob, Wolfgang ^{[17
]}

Schneider, Meike ^{[20
]}

Sleiman, Nassim ^{[20
]}

Weisser, Martin ^{[17
]}

Carlo-Stella, Carmelo ^{[21
,22
]}

机构：

[1] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Royal Melbourne Hosp, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[3] Rigshospitalet, Copenhagen, Denmark

[4] CHU Lille, Lille, France

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[7] CHU Bordeaux, Bordeaux, France

[8] Ist Nazl Tumori, Milan, Italy

[9] NHS Univ Coll London Hosp, London, England

[10] CHU Nantes, Nantes, France

[11] Marques Valdecilla Univ Hosp, Santander, Spain

[12] Univ Ziekenhuis Gent, Ghent, Belgium

[13] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[14] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedo, Bologna, Italy

[15] Univ Bologna, Bologna, Italy

[16] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[17] Roche Innovat Ctr Munich, Penzberg, Germany

[18] Roche Innovat Ctr Zurich, Zurich, Switzerland

[19] Roche Innovat Ctr Welwyn, Welwyn Garden City, England

[20] Roche Innovat Ctr Basel, Basel, Switzerland

[21] Humanitas Univ, Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy

[22] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-05

引用

页码：S3 / S4

页数：2

共 50 条

[21] RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
Carlo-Stella, Carmelo
Mazza, Rita
Manier, Salomon
Facon, Thierry
Yoon, Sung-Soo
Koh, Youngil
Harrison, Simon J.
Er, Jeremy
Pinto, Antonio
Volzone, Francesco
Perrone, Giulia
Corradini, Paolo
Cazaubiel, Titouan
Hulin, Cyrille
Touzeau, Cyrille
Moreau, Philippe
Ocio, Enrique M.
Gaisan, Carmen Maria Montes
Popat, Rakesh
Leong, Sarah
Offner, Fritz
Otero, Paula Rodriguez
Alfonso-Pierola, Ana
Broeske, Ann-Marie E.
Dekhtiarenko, Iryna
Helms, Hans-Joachim
Belli, Sara
Rossmann, Eva
Fauti, Tanja
Eckmann, Jan
Moore, Tom
Schneider, Meike
Jacob, Wolfgang
Weisser, Martin
Hutchings, Martin
Riley, Caroline Hasselbalch
BLOOD, 2022, 140
[22] The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
Hammons, Lindsay
Szabo, Aniko
Janardan, Abhishek
Bhatlapenumarthi, Vineel
Annyapu, Evanka
Dhakal, Binod
Al Hadidi, Samer
Radhakrishnan, Sabarinath Venniyil
Narra, Ravi
Bhutani, Divaya
Thanendrarajan, Sharmilan
Janz, Siegfried
Zangari, Maurizio
Lentzsch, Suzanne
van Rhee, Frits
Crescencio, Juan Carlos Rico
D'Souza, Anita
Chakraborty, Rajshekhar
Mohan, Meera
Schinke, Carolina
HAEMATOLOGICA, 2024, 109 (03) : 906 - 914
[23] Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)
Gill, Sarvarinder Kaur
Fleming, Erika
Gebre, Helen
Bangolo, Ayrton, I
Siegel, David S.
Vesole, David H.
Biran, Noa
Parmar, Harsh
Phull, Pooja
BLOOD, 2024, 144 : 7047 - 7048
[24] REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Madduri, Deepu
Rosko, Ashley
Brayer, Jason
Zonder, Jeffrey
Bensinger, William I.
Li, Jingjin
Xu, Linzhi
Adriaens, Lieve
Chokshi, Dhruti
Zhang, Weijiang
Boyapati, Anita
Sharma, Manish
Seebach, Frank
Sirulnik, L. Andres
Weinreich, David M.
Yancopoulos, George D.
Dhodapkar, Madhav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
BLOOD, 2020, 136
[25] Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
Gengenbach, Laura
Graziani, Giulia
Reinhardt, Heike
Roesner, Amelie
Braun, Magdalena
Moeller, Mandy-Deborah
Greil, Christine
Waesch, Ralph
Engelhardt, Monika
CANCERS, 2021, 13 (17)
[26] Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Valdes, Cesar Rodriguez
Voorhees, Peter M.
D'Souza, Anita
Chung, Alfred
Tuchman, Sascha
Safah, Hana
Mckay, John T.
Weisel, Katja C.
Teipel, Raphael
Korde, Neha
Vij, Ravi
Bueno, Orlando Felix
Rosenberg, Tanya
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth
Ahsan, Aarif
Li , Xin
Jin, Ziyi
Talati, Chetasi
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma ( RRMM)
Kapoor, Prashant
Stevens, Don A.
Leleu, Xavier
Merzoug, Karim Belhadj
Karlin, Lionel
Manier, Salomon
Chalopin, Thomas
Hulin, Cyrille
Perrot, Aurore
Berdeja, Jesus G.
Chase, Cristiana Costa
Touzeau, Cyrille
Moreau, Philippe
Mohan, Sanjay
Lesokhin, Alexander
Huff, Carol
Vesole, David H.
Richter, Joshua
Matous, Jeffrey
Wolff, Eileen
Shah, Tejas
Koch-Olsen, Jeppe
Garton, Andrew
Menon, Vinu
Gn, Sunitha
Perro, Mario
Zhukovsky, Eugene
Konto, Cyril
Pacaud, Lida
Mohty, Mohamad
BLOOD, 2023, 142
[28] BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy
Joiner, Laura
Costa, Luciano
Giri, Smith
Ravi, Gayathri
Godby, Kelly
Hagedorn, Caitlin
Bal, Susan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S61 - S62
[29] Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma
Aronson, Elizabeth
Purcell, Kiah
Aponte, Annel
Louw, Karen
Catamero, Donna
Lamb, Angela
Kirke, Diana
Lucas, Aimee
Jagannath, Sundar
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S195 - S195
[30] Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Mohan, Sanjay R.
Chase, Cristiana Costa
Berdeja, Jesus G.
Karlin, Lionel
Belhadj, Karim
Perrot, Aurore
Moreau, Philippe
Touzeau, Cyrille
Chalopin, Thomas
Lesokhin, Alexander M.
Huff, Carol Ann
Vesole, David H.
Richter, Joshua
Matous, Jeffrey, V
Proscurshim, Igor
Wolff, Eileen
Gudi, Girish
Garton, Andrew
Menon, Vinu
Gn, Sunitha
Salhi, Yacine
Feldman, Eric J.
Mohty, Mohamad
BLOOD, 2022, 140 : 7264 - 7266

← 1 2 3 4 5 →